Quent Capital’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.9K Buy
159
+32
+25% +$8.43K ﹤0.01% 842
2026
Q2
$28.8K Hold
127
– – ﹤0.01% 968
2026
Q1
$21.9K Sell
127
-6
-5% -$1.11K ﹤0.01% 967
2025
Q4
$26.5K Sell
133
-12
-8% -$2.18K ﹤0.01% 920
2025
Q3
$22.7K Buy
+145
New +$23K ﹤0.01% 821
2025
Q2
– Sell
-160
Closed -$24.1K – 486
2025
Q1
$24.1K Buy
160
+4
+3% +$671 ﹤0.01% 726
2024
Q4
$28.8K Hold
156
– – ﹤0.01% 718
2024
Q3
$30.7K Hold
156
– – ﹤0.01% 782
2024
Q2
$32.2K Sell
156
-24
-13% -$5.44K ﹤0.01% 742
2024
Q1
$48.8K Buy
180
+1
+0.6% +$239 0.01% 671
2023
Q4
$42.3K Sell
179
-12
-6% -$2.36K 0.01% 660
2023
Q3
$37.4K Sell
191
-13
-6% -$2.67K 0.01% 659
2023
Q2
$42.9K Hold
204
– – 0.01% 626
2023
Q1
$41.2K Buy
204
+6
+3% +$1.36K 0.01% 638
2022
Q4
$43.1K Hold
198
– – 0.01% 620
2022
Q3
$39K Buy
198
+44
+29% +$9.5K 0.01% 608
2022
Q2
$33K Hold
154
– – 0.01% 616
2022
Q1
$44K Buy
154
+38
+33% +$11.7K 0.01% 630
2021
Q4
$44K Buy
+116
New +$45.1K 0.01% 580

Other funds holding CRL

Quent Capital's CRL Position: Q3 2026 in Review

Quent Capital increased its Charles River Laboratories (CRL) stake by 25% in Q3 2026, buying an estimated $8.43K and bringing the position to 159 shares worth $46.9K. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Quent Capital first reported a position in CRL in Q4 2021 and has held it in 19 quarters since. The position peaked at $48.8K in Q1 2024. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Quent Capital held 159 shares of Charles River Laboratories worth $46.9K as of Q3 2026.
  • Quent Capital bought 32 Charles River Laboratories shares in Q3 2026, an estimated $8.43K.
  • Charles River Laboratories made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #842 holding.
  • Quent Capital first reported a position in Charles River Laboratories in Q4 2021 and has held it in 19 quarters since.
  • Quent Capital's Charles River Laboratories position peaked at $48.8K in Q1 2024.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.